



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad - 500 081, Telangana, INDIA.
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com
CIN: L24110TG1991PLC012471

Dated August 29, 2019

To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES; BSE: 532482

Sub: Press Release

Dear Sir,



Please find herewith a copy of Press Release issued by the Company for divestment of its stake in Granules OmniChem Private Limited, a Joint Venture Company located in India.

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours sincerely,

For GRANULES INDIA LIMITED



CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)

Encl as above



Press Release

Granules India Limited to divest its stake in its Joint Venture located in India

Hyderabad, August 29, 2019: Granules India Ltd., today announced its intention to divest its entire equity shareholding in Granules OmniChem Private Limited (GOC) by selling its stake to its joint venture partner. GOC is an equal joint venture between Granules India Limited and S.A. Ajinomoto Omnicem N.V. (now doing business as Ajinomoto Bio-Pharma Services), an integrated contract development and manufacturing organization. The manufacturing facility of this joint venture entity is located in Visakhapatnam, India. Conclusion of this transaction is subject to fulfilment of certain closing conditions as well as customary government approvals.

“The proposed divestment of our 50% stake in the joint venture aligns with our focus on strengthening our core area of business. With this transaction, S.A. Ajinomoto Omnicem N.V. will take over full control of the CRAMS business. Through this deal we would like to extend our support to our joint venture partner for their business plan to integrate their small and large molecule businesses which in turn strengthens their business operation and client relations. I believe this is a win-win situation for both the companies as we continue to build upon our business model based on our area of concentration.” said Mr. Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India Limited.

About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India is a growing pharmaceutical manufacturing company with best in class facilities and is committed to operational excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) which gives the customers flexibility and choice. Granules support customers with unique value, extensive product range, and proactive solutions. The Company’s global presence extends to over 250 customers in 60 countries through offices in India, U.S., and U.K. The Company has 8 manufacturing facilities out of which 6 are located in India, 1 in China and 1 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.

Contacts:

Sumanta Bajpayee
Head - Corporate Finance, Treasury & Investor Relations
040-30663572
sumanta.bajpayee@granulesindia.com

Chaitanya Tummala
Company Secretary
040-30663614
chaitanya.tummala@granulesindia.com